GLP-1 receptor agonists are a type of non-insulin medication used to treat type 2 diabetes in conjunction with diet and exercise. These medications are used to help lower blood glucose levels and hemoglobin A1C, as well as to aid in weight loss. GLP-1 signals the hypothalamus, the part of the brain in charge of appetite and thirst, to consume less water and food. In 2021, the global glucagon-like peptide 1 (GLP-1) market was valued at US$16.53 billion, and is probable to reach US$24.10 billion by 2027.

The market would gain traction in the upcoming years with an increase in the number of products approved that help with the treatment of diabetes. It is anticipated that an increase in mergers and acquisitions would support the market in the coming years. The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.

Scope of the Report

The report titled “Global Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of Administration (Injectable and Oral Medication), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027”, includes:

-- An in-depth analysis of the global glucagon-like peptide 1 (GLP-1) market by value, by product, by route of administration, by region, etc.

-- The regional analysis of the glucagon-like peptide 1 (GLP-1) market, including the following regions:

North America (The US, Canada and Mexico)
Asia Pacific (China, Japan, India, Australia South Korea and Rest of Asia Pacific)
Europe (Germany, UK, Spain, Italy, France and Rest of Europe)
Latin America
Middle East and Africa

-- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

-- Provides an analysis of the COVID-19 impact on the global glucagon-like peptide 1 (GLP-1) market, with post COVID impact analysis.

-- Assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall glucagon-like peptide 1 (GLP-1) market has also been forecasted for the period 2022-2027, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

-- Evaluation of the potential role of glucagon-like peptide 1 (GLP-1) to improve the market status.

-- Identification of new technological developments, R&D activities, and collaborations occurring in the glucagon-like peptide 1 (GLP-1) market.

-- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

-- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

-- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.

For further details, kindly visit :

https://www.daedal-research.com/pharma-healthcare/global-glucagon-like-peptide-1-glp-1-market-size-and-trends-with-impact-of-covid-19-and-forecast-up-to-2027

Rajeev Kumar
(Business Development Manager)
Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Mobile: +91-9811715635
Tel: +91-120-4553017
Mail ID - [email protected]